

**Extract of Consolidated Audited Financial Results
for the quarter and year ended 31st March, 2016**

(₹ in Crores except per share data)

Particulars	Quarter Ended	Year Ended	Quarter Ended
	31-Mar-2016	31-Mar-2016	31-Mar-2015
Total Income from operations (net)	1499	6676	1154
Net Profit / (Loss) from ordinary activities after tax	357	1722	130
Net Profit / (Loss) for the period after tax (after Extraordinary items)	357	1722	130
Equity Share Capital	85	85	85
Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	3304	3304	2406
Earnings per share (before extraordinary items)(of ₹ 5/- each):			
Basic	21.13	101.78	7.70
Diluted	21.13	101.78	7.70
Earnings per share (after extraordinary items)(of ₹ 5/- each):			
Basic	21.13	101.78	7.70
Diluted	21.13	101.78	7.70

Notes:

- 1 Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited :

(₹ in Crores)

Particulars	Quarter ended	Year Ended	Quarter ended
	31-Mar-2016	31-Mar-2016	31-Mar-2015
Net income from operations	986	5429	897
Profit before tax	161	2361	145
Profit after tax	121	1763	103

- 2 The Company acquired 100% stake in formulation facility of Zyg Pharma Private Limited on 17th July, 2015. The Honourable High Court of Gujarat vide its Order dated 11th February, 2016, has sanctioned the Scheme of Amalgamation of Zyg Pharma Private Limited with Torrent Pharmaceuticals Limited under Sections 391 to 394 and other applicable provisions of the Companies Act, 1956 ("the Act") with effect from Appointed Date of 1st October, 2015. The figures for the quarter and year ended 31st March, 2016 are after giving effect to the amalgamation in books of accounts. Hence the quarter ended figures, to that extent are not comparable.
- 3 The Board of Directors have approved payment of normal dividend as interim dividend of ₹ 20.00 and a special dividend as second interim dividend of ₹ 15.00 per equity share of ₹ 5.00 each fully paid up. Total dividend for the current year is ₹ 35.00 (previous year ₹ 11.25) per equity share of ₹ 5.00 each fully paid up. Considering the overall distribution, the Board has decided not to recommend distribution of any further dividend.
- 4 The above is an extract of the detailed format of Financial Results for the quarter and year ended 31st March, 2016 filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the same, along with the notes, are available on www.nscindia.com, www.bscindia.com and on the Company's website www.torrentpharma.com.